Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus

Liver Transpl Surg. 1998 Nov;4(6):448-54. doi: 10.1002/lt.500040605.


The outcome of hepatitis C virus (HCV) infection on patient and graft survival after orthotopic liver transplantation (OLT) has been controversial. An earlier experience with a higher dose of tacrolimus (>/=0.1 mg/kg/d intravenously and >/=0.2 mg/kg/d orally) was associated with a worse clinical outcome in patients infected with HCV. The clinical outcome of 183 liver transplant recipients with end-stage liver disease (ESLD) secondary to HCV infection (HCV group) was compared with a contemporary cohort of 556 patients with HCV infection who underwent transplantation for nonviral, nonmalignant ESLD (control group). All patients were prospectively screened for anti-HCV antibodies and HCV RNA by reverse-transcriptase polymerase chain reaction. All OLT patients were receiving low-dose tacrolimus immunosuppression. Cumulative patient survival rates for the HCV group were 80% after 1 year and 75% after 3 years compared with rates of 84% and 78%, respectively, in the control group (P = .452). Primary graft survival rates at the same time intervals for the HCV group and the control group were 72% and 77.5% at 1 year and 67% and 72% at 3 years, respectively (P = .144). The incidence of re-transplantation (re-OLT) in the HCV group and the control group was 12.6% and 10.4%, respectively (P = .42). Chronic HCV infection as an indication for OLT with a lower dose of tacrolimus immunosuppression (</=0.05 mg/kg/d intravenously and </=0.1 mg/kg/d orally) is associated with a similar patient and graft survival as those without HCV infection.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Chi-Square Distribution
  • Cohort Studies
  • Female
  • Graft Rejection / immunology
  • Graft Survival / immunology
  • Hepacivirus / genetics
  • Hepatitis C / immunology
  • Hepatitis C / surgery*
  • Hepatitis C Antibodies / blood
  • Humans
  • Immunoenzyme Techniques
  • Immunosuppressive Agents / administration & dosage*
  • Liver Transplantation / immunology
  • Liver Transplantation / mortality*
  • Male
  • Middle Aged
  • Proportional Hazards Models
  • RNA, Viral / blood
  • Reoperation
  • Retrospective Studies
  • Reverse Transcriptase Polymerase Chain Reaction
  • Survival Rate
  • Tacrolimus / administration & dosage*
  • Treatment Outcome


  • Hepatitis C Antibodies
  • Immunosuppressive Agents
  • RNA, Viral
  • Tacrolimus